Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient Name**	**Purpose**	**Specific requirements**
2852	KADSURA COCCINEA	A, H	
2853	KAEMPFERIA GALANGA	A, H	
2854	KALMIA LATIFOLIA	A, H	Beta-arbutin is a mandatory component of Kalmia latifolia. When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin. When for dermal application exclusively to the face: a) the concentration of beta-arbutin in the medicine must not be more than 7%; b) hydroquinone is a mandatory component; and c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%. When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.
2855	KAOLIN	E	
2856	KELP DRY	A, H	Iodine is a mandatory component of Kelp dry. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Volume 4

			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2857	KELP POWDER	A, E, H	Iodine is a mandatory component of Kelp powder. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2858	KERATIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2859	KEROSENE	E, H	Only for use as a homoeopathic ingredient. When used in liquid preparations, the concentration in the medicine must be no more than 25%.
2860	KHAYA SENEGALENSIS	A, E	The maximum daily dose of the medicine must not contain more than the equivalent of 1 g dry bark of Khaya senegalensis. The following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (LONGUSE) ‘Not for prolonged use. May harm liver';

			- (GEN2) ‘If symptoms persist, seek the advice of a healthcare professional’; - (CHILD3) ‘Use in children under 12 years is not recommended’; and - (7DAYS) 'Do not use for more than 7 days'.
2861	KIDNEY BEAN	E	
2862	KIRSCH	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2863	KIWI FRUIT	E	
2864	KNAUTIA ARVENSIS	A, H	
2865	KOREAN GINSENG ROOT DRY	A, H	
2866	KOREAN GINSENG ROOT POWDER	A, H	
2867	KRAMERIA IXINE	A, H	
2868	KRAMERIA LAPPACEA	A, H	
2869	KUNZEA AMBIGUA	A	Only for use when the plant preparation is essential oil. Only for use when the route of administration is topical or inhalation. When the dosage form is essential oil, a restricted flow insert must be fitted on the container and the medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' - (EXTERN) 'For external use only' - (UNDILU) 'Not to be applied undiluted to the skin except on the

Volume 4

			advice of a health care practitioner'. When the dosage form is other than essential oil, the maximum concentration in topical medicines must be no more than 25% w/w and the medicine requires the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' - (EXTERN) 'For external use only'.
2870	L-BORNEOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2871	L-BORNYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2872	L-CARVONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

			medicine must be no more 1%.
2873	L-LIMONENE	E	L-limonene must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation or a fragrance proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations containing l-limonene must not be more than 5% of the total medicine. The total concentration of fragrance proprietary excipient formulations containing l-limonene must not be more than 1% of the total medicine.
2874	L-LINALOOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2875	L-MENTHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2876	L-MENTHYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

Volume 4

			flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2877	L-ROSE OXIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2878	LABDANUM ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2879	LABDANUM GUM EXTRACT ETHYL ESTER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance and the total fragrance concentration in a medicine is no more than 1%.
2880	LABDANUM OIL	A, E, H	
2881	LABURNUM ANAGYROIDES	A, H	Sparteine is a mandatory component of Laburnum anagyroides. The concentration of sparteine in the medicine must be no more than 0.001%.
2882	LACTALBUMIN	E	

2883	LACTIC ACID	A, E, H	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing form time to time. Sponsors should consider the impact of excipients containing alpha hydroxy acids on the sensitivity of the skin to sunlight and should ensure the finished medicine is safe for its intended purpose.
2884	LACTITOL	E	
2885	LACTITOL MONOHYDRATE	E	
2886	LACTO-N-NEOTETRAOSE	A	Only to be used in a medicine where Glycom A/S (Client ID 76983), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 20 August 2023. Lactose is a mandatory component of lacto-N-neotetraose. The route of administration for medicines that contain lacto-N-neotetraose must be limited to oral. The maximum recommended daily dose of the medicine must not provide more than: (a) 1.5 g of lacto-N-neotetraose to individuals aged 4 years and older; and (b) 0.6 g of lacto-N-neotetraose to individuals aged up to 3 years (inclusive).

Volume 4

			The requirements specified in paragraph (a) below apply to a medicine that contains the ingredient that is released for supply after 20 August 2023: (a) One of the following statements is required on the medicine label: (i) When the medicine is only for use in individuals aged 2 years and above: 'Not to be taken on the same day with other products containing lacto-N-neotetraose' (or words to that effect); or (ii) When the medicine is for use in children aged less than 2 years: 'Not to be taken on the same day with breastmilk or other products containing lacto-N-neotetraose' (or words to that effect).
2887	LACTO-N-TETRAOSE	A	Only to be used in a medicine where Glycom A/S (Client ID 76983), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 24 January 2024. Lactose is a mandatory component of lacto-N-tetraose. The route of administration for medicines that contain lacto-N-tetraose must be limited to oral. The maximum recommended daily dose of the medicine must not provide more than: a) 2 g of lacto-N-tetraose to individuals aged 1 year and older; and b) 0.6 g of lacto-N-tetraose to individuals aged more than 6

			months to 11 months (inclusive); and c) 0.8 g of lacto-N-tetraose to individuals aged up to 6 months (inclusive). One of the following statements (or words to that effect) is required on the medicine label: a) When the medicine is only for use in individuals aged 2 years and above: 'Not to be taken on the same day with other products containing lacto-N-tetraose'; or b) When the medicine is for use in children aged less than 2 years: 'Not to be taken on the same day with breastmilk or other products containing lacto-N-tetraose'.
2888	LACTOBACILLUS ACIDOPHILUS	A	
2889	LACTOBACILLUS AMYLOVORUS	A	
2890	LACTOBACILLUS BREVIS	A	
2891	LACTOBACILLUS CASEI	A	
2892	LACTOBACILLUS CASEI SUBSP. BIOVAR CASEI	A	
2893	LACTOBACILLUS CRISPATUS	A	
2894	LACTOBACILLUS DELBRUECKII SSP BULGARICUS	A	
2895	LACTOBACILLUS DELBRUECKII SSP LACTIS	A	
2896	LACTOBACILLUS FERMENTUM	A	
2897	LACTOBACILLUS GALLINARUM	A	
2898	LACTOBACILLUS GASSERI	A	
2899	LACTOBACILLUS HELVETICUS	A	
2900	LACTOBACILLUS JOHNSONII	A	
2901	LACTOBACILLUS KEFIRANOFACIENS	A	
2902	LACTOBACILLUS KEFIRGRANUM	A	
2903	LACTOBACILLUS KEFIRI	A	

Volume 4

2904	LACTOBACILLUS PARACASEI	A	
2905	LACTOBACILLUS PARACASEI SUBSP. PARACASEI	A	
2906	LACTOBACILLUS PLANTARUM	A	
2907	LACTOBACILLUS REUTERI	A	
2908	LACTOBACILLUS RHAMNOSUS	A	
2909	LACTOBACILLUS SALIVARIUS SSP SALICINIUS	A	
2910	LACTOBACILLUS SALIVARIUS SSP SALIVARIUS	A	
2911	LACTOBIONIC ACID	E	Only for use in topical medicines for dermal application.
2912	LACTOSCATONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2913	LACTOSE	E	
2914	LACTOSE MONOHYDRATE	E	
2915	LACTUCA SATIVA	A, H	
2916	LACTUCA VIROSA	A, H	
2917	LACTULOSE	E	
2918	LACTULOSE SOLUTION	A	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing form time to time.
2919	LAGENARIA VULGARIS	A, H	
2920	LAMINARIA CLOUSTONI	A, E, H	Iodine is a mandatory component of Laminaria cloustoni. Only for external use when the concentration of iodine in the medicine (excluding salts

			derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2921	LAMINARIA DIGITATA	A, E, H	Iodine is a mandatory component of Laminaria digitata. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2922	LAMINARIA JAPONICA	A, E, H	Iodine is a mandatory component of Laminaria japonica. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2923	LAMIUM ALBUM	A, H	
2924	LANETH-5	E	Only for use in topical medicines for dermal application.
2925	LANOLIN ALCOHOL	E	Only for use in topical medicines for dermal application.
2926	LANOLIN OIL	E	Only for use in topical medicines for dermal application.

Volume 4

2927	LANOLIN WAX	E	Only for use in topical medicines for dermal application.
2928	LANTANA CAMARA	A, H	The maximum recommended daily dose must contain no more than 1mg of the equivalent dry herbal material of Lantana camara.
2929	LARIX ARABINOGALACTAN	A, E	The concentration of polysaccharides in the ingredient must be greater than or equal to 85%. The ingredient must be derived from Larix occidentalis or Larix larcinia. Only for use in oral medicines or topical medicines for dermal application, and not to be included in topical products intended for use in the eye. The maximum recommended daily dose of Larix arabinogalactan in oral medicines must not be more than 15 grams. The concentration of Larix arabinogalactan in topical medicines for dermal application must not exceed 5.0%.
2930	LARIX DECIDUA	A, H	
2931	LARIX KAEMPFERI	A, H	The maximum recommended daily dose must be no more than 1 mg of the equivalent dry herbal material of Larix kaempferi.
2932	LARREA TRIDENTATA	A, H	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is: - listed in the Register before 1 March 2023; and - released for supply before 1

			March 2024: (a) One of the following warning statements is required on the medicine label: (i) (CHAP) 'WARNING: Chaparral may harm the liver in some people - use only under supervision of a health care professional'; or (ii) (CHAP1) 'In rare cases, Larrea tridentata may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain or dark urine.' The requirement specified in paragraph (b) below applies to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2023; or - released for supply on or after 1 March 2024. (b) The following warning statement is required on the medicine label: (CHAP1) 'In rare cases, Larrea tridentata may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain or dark urine.'
2933	LATHYRUS SATIVUS	A, H	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Lathyrus sativus. The medicine must not contain lathyrogenic amino acids.
2934	LAURAMINE OXIDE	E	
2935	LAUREL LEAF OIL	A, H	When the total concentration of bay oil in the medicine is more

Volume 4

			than 25%: (a) the nominal capacity of the container must not be more than 25 mL; (b) the container must be fitted with a restricted flow insert; (c) the following warning statements are required on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); - (NTAKEN) 'Not to be taken'; and (d) when the nominal capacity of the container is greater than 15 mL, the container must also be fitted with a child resistant closure.
2936	LAURETH-10	E	Only for use in topical medicines for dermal application.
2937	LAURETH-12	E	Only for use in topical medicines for dermal application.
2938	LAURETH-2	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.4%. Residual levels of ethylene oxide (and related substances) must be kept below the level of detection.
2939	LAURETH-23	E	Only for use in topical medicines for dermal application.
2940	LAURETH-3	E	Only for use in topical medicines for dermal application.
2941	LAURETH-4	E	Only for use in topical medicines for dermal application.

2942	LAURETH-7	E	Only for use in topical medicines for dermal application.
2943	LAURETH-8	E	
2944	LAURIC ACID	A, E	When for use as an active ingredient is for use in oral medicines only and the maximum recommended daily dose must not exceed 1500 mg.
2945	LAURIL MACROGOL 400 DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5%.
2946	LAUROMACROGOL 400	E	Only for use in topical medicines for dermal application.
2947	LAUROYL LYSINE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5.0%.
2948	LAURUS NOBILIS	A, E, H	When the plant preparation is oil or distillate, and the concentration of bay oil or distillate in the medicine is greater than 25%: (a) the nominal capacity of the container must not be more than 25 mL; (b) the container must be fitted with a restricted flow insert; (c) the following warning statements are required on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect);

Volume 4

			- (NTAKEN) 'Not to be taken'; and (d) when the nominal capacity of the container is greater than 15 mL, the container must also be fitted with a child resistant closure.
2949	LAURYL ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a coating solution, flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2950	LAURYL BETAINE	E	Only for use in topical medicines for dermal application.
2951	LAURYL GLUCOSIDE	E	Only for use as an excipient ingredient in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 12%.
2952	LAURYL LACTATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%. Sponsors should consider the impact of excipients containing alpha hydroxy acids on the sensitivity of the skin to sunlight and should ensure the finished medicine is safe for its intended purpose.

2953	LAURYL PCA	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
2954	LAURYL PEG-10 TRIS(TRIMETHYLSILOXY)SILYL ETHYL DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
2955	LAURYL PEG-9 POLYDIMETHYLSILOXYETHYL DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin. The concentration in the medicine must be no more than 3.5%.
2956	LAURYL PEG/PPG-18/18 METHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 9%. Residual levels of ethylene oxide (and related substances) must be kept below the level of detection.
2957	LAURYL POLYGLUCOSE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must not exceed 1% in leave-on medicines and 3% in wash-on/wash-off medicines.

Volume 4

2958	LAURYL PYRROLIDONE	E	Only for use in topical medicines for dermal application.
2959	LAURYLDIMONIUM HYDROXYPROPYL HYDROLYSED COLLAGEN	E	Only for use in topical medicines for dermal application.
2960	LAURYLDIMONIUM HYDROXYPROPYL HYDROLYSED SOY PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.007%.
2961	LAURYLMETICONE COPOLYOL	E	Only for use in topical medicines for dermal application.
2962	LAVANDIN OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2963	LAVANDIN OIL ABRIAL	A, E, H	
2964	LAVANDIN OIL GROSSO	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2965	LAVANDULA ANGUSTIFOLIA	A, E, H	Camphor is a mandatory component of Lavandula angustifolia. In solid and semi solid preparations, the concentration of camphor must be no more than

			12.5%. In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.
2966	LAVANDULA ANGUSTIFOLIA SUBSP. ANGUSTIFOLIA	A, E, H	Camphor is a mandatory component of Lavandula angustifolia subsp. angustifolia. In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%. In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.
2967	LAVANDULA X INTERMEDIA	A, E, H	Camphor is a mandatory component of Lavandula x intermedia. In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.
2968	LAVENDER OIL	A, E, H	
2969	LAWSONIA INERMIS	A, H	
2970	LEAD	H	Only for use as an active homoeopathic ingredient. The concentration in the medicine must be no more than 0.001%.
2971	LEAD ACETATE	H	Only for use as an active homoeopathic ingredient.
2972	LEAF ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

Volume 4

2973	LECITHIN	A, E	
2974	LEDEBOURIELLA SESELOIDES	A, H	
2975	LEDUM PALUSTRE	A, H	Beta-arbutin is a mandatory component of Ledum palustre. When for dermal application exclusively to the face: a) the concentration of beta-arbutin in the medicine must not be more than 7%; b) hydroquinone is a mandatory component; and c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%. When for topical use other than dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%. When the route of administration is other than topical, the maximum recommended daily dose must not contain more than 0.001 mg of the equivalent dry herbal material of Ledum palustre.
2976	LEMNA MINOR	A, H	
2977	LEMON	E	When used internally, oxedrine is a mandatory component of lemon. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
2978	LEMON BALM LEAF DRY	A, H	
2979	LEMON BALM LEAF POWDER	A, E, H	
2980	LEMON OIL	A, E, H	When used internally, oxedrine is a mandatory component of lemon oil. The quantity of oxedrine in the

			maximum recommended daily dose must be no more than 30 milligrams. The warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) steam distilled or rectified; or b) for internal use; or c) contains 0.05% or less of lemon oil; or d) for use in soaps or bath or shower gels that are washed off the skin.
2981	LEMON OIL DISTILLED	A, E, H	When used internally, oxedrine is a mandatory component of lemon oil distilled. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
2982	LEMON OIL TERPENELESS	A, E, H	When used internally, oxedrine is a mandatory component of lemon oil terpeneless. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
2983	LEMON OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Volume 4

2984	LEMON PEEL DRIED	A, E, H	When used internally, oxedrine is a mandatory component of lemon peel dried. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
2985	LEMONGRASS OIL	A, E, H	
2986	LENS CULINARIS	A, H	
2987	LENTIL	E	
2988	LENTINULA EDODES	A, E, H	
2989	LEONTOPODIUM ALPINUM	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
2990	LEONURUS CARDIACA	A, E, H	
2991	LEONURUS SIBIRICUS	A, E, H	
2992	LEPIDIUM APETALUM	A, H	
2993	LEPIDIUM MEYENII	A	The route of administration for medicines that contain Lepidium meyenii must be limited to oral. The ingredient must consist of the dried tuber of Lepidium meyenii only. The maximum recommended daily dose of the medicine must not provide more than 3.5 g of Lepidium meyenii dried tuber (or its extract equivalent).
2994	LEPTOSPERMUM PETERSONII	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more 5%.
2995	LEPTOSPERMUM SCOPARIUM OIL	A	Only for use as an active ingredient when the route of

			administration is topical or oral application in a mouthwash preparation. If the concentration is more than 25%, the nominal capacity of the container must be no more than 25mL. When the concentration is more than 25%, and the nominal capacity of the container less than 15mL, a restricted flow insert must be fitted on the container and requires the following warning statements on the medicine label: - (CHILD) ‘Keep out of reach of children' (or word to that effect) - (NTAKEN) ‘Not to be taken’ When the concentration is more than 25%, the nominal capacity of the container is more than 15 mL but no more than 25 mL, a child resistant closure and restricted flow insert must be fitted on the container and requires the following warning statements on the medicine label: - (CHILD) ‘Keep out of reach of children' (or word to that effect) - (NTAKEN) ‘Not to be taken’
2996	LESPEDEZA CAPITATA	A, H	
2997	LETTUCE	E	
2998	LEUCINE	A, E	
2999	LEUZEA UNIFLORA	A, H	
3000	LEVISTICUM OFFICINALE	A, H	
3001	LEVOCARNITINE	A	
3002	LEVOCARNITINE FUMARATE	A	
3003	LEVOCARNITINE HYDROCHLORIDE	A	
3004	LEVOCARNITINE MAGNESIUM CITRATE	A	
3005	LEVOCARNITINE TARTRATE	A	

Volume 4

3006	LEVOMEFOLATE CALCIUM	A	Available for medicines intended for internal use only. Levomefolic acid is a mandatory component of levomefolate calcium. The maximum recommended daily dose must not provide more than 500 micrograms of levomefolic acid from levomefolate calcium. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
3007	LEVOMEFOLATE GLUCOSAMINE	A	Available for medicines intended for internal use only. Levomefolic acid is a mandatory component of levomefolate glucosamine. The maximum recommended daily dose must not provide more than 500 micrograms of levomefolic acid from levomefolate glucosamine. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
3008	LEVOTHYROXINE SODIUM	H	Only for use as an active homoeopathic ingredient.
3009	LEVULINIC ACID	E	Permitted for use only in

			combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3010	LIGHT KAOLIN	E	
3011	LIGHT LIQUID PARAFFIN	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
3012	LIGHT MAGNESIUM OXIDE	A, E, H	Magnesium is a mandatory component of light magnesium oxide. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect

			or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3013	LIGUSTICUM SINENSE	A, H	
3014	LIGUSTICUM STRIATUM	A, E, H	
3015	LIGUSTRUM LUCIDUM	A, H	
3016	LILIUM BROWNII	A, H	
3017	LILIUM CANDIDUM	A, E, H	
3018	LILIUM LANCIFOLIUM	A, H	
3019	LILIUM LONGIFLORUM	A, H	
3020	LIME FRUIT	E	
3021	LIME OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3022	LIME OIL COLDPRESSED	A, E, H	The warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) contains 0.5% or less of lime oil coldpressed; or c) for use in soaps or bath or shower gels that are washed off the skin.
3023	LIME OIL DISTILLED	A, E, H	The warning statement (SENS) 'Application to skin may increase

			sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) contains 0.5% or less of lime oil distilled; or c) for use in soaps or bath or shower gels that are washed off the skin.
3024	LIME OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3025	LIME OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3026	LIME TREE FLOWER DRY	A, H	
3027	LIME TREE FLOWER POWDER	A, H	
3028	LIME, ESSENCE	E	
3029	LIMES TERPENES	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3030	LIMONENE	E	When for oral use, the quantity

Volume 4

			must be no more than 10 mg per maximum recommended daily dose.
3031	LINALOOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3032	LINALOOL OXIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3033	LINALYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3034	LINALYL ACETATE	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in

			combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
3035	LINALYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3036	LINALYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3037	LINALYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3038	LINALYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Volume 4

3039	LINALYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3040	LINALYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3041	LINDERA STRYCHNIFOLIA	A, H	
3042	LINOLEAMIDOPROPYL PG-DIMONIUM CHLORIDE PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
3043	LINOLEIC ACID	E	
3044	LINOLENIC ACID	E	
3045	LINSEED DRY	A, E, H	
3046	LINSEED OIL	A, E, H	
3047	LINSEED OIL FATTY ACIDS	E	Linseed oil fatty acids must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations

			containing linseed oil fatty acids must not be more than 5% of the total medicine.
3048	LINSEED POWDER	A, E, H	
3049	LINUM USITATISSIMUM	A, E, H	
3050	LIPASE	A	Lipase must only be derived from Rhizopus oryzae and must comply with the relevant compositional guideline.
3051	LIPPIA DULCIS	A, H	
3052	LIQUID GLUCOSE	E	
3053	LIQUID PARAFFIN	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
3054	LIQUIDAMBAR FORMOSANA	A, H	
3055	LIQUIDAMBAR ORIENTALIS	A, H	
3056	LIQUIDAMBAR STYRACIFLUA	A, E, H	
3057	LIQUIDAMBAR STYRACIFLUA RESIN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3058	LIQUIDAMBAR TAIWANIANA	A, H	
3059	LIQUORICE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Volume 4

3060	LIQUORICE DRY	A, E, H	
3061	LIQUORICE LIQUID EXTRACT	A, E, H	
3062	LIQUORICE POWDER	A, E, H	
3063	LITCHI CHINENSIS	A, H	
3064	LITHIUM CARBONATE	H	Only for use as an active homoeopathic ingredient.
3065	LITHOSPERMUM OFFICINALE	A, H	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Lithospermum officinale.
3066	LITSEA CUBEBA	A, E, H	
3067	LITSEA CUBEBA OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3068	LOBARIA PULMONARIA	A, H	
3069	LOBELIA DRY	A, H	The concentration in the medicine must be no more than 0.001% or 10mg/kg or 10ml/L or 10 ppm unless the medicine is administered by inhalation.
3070	LOBELIA INFLATA	A, H	The concentration in the medicine must be no more than 0.001% or 10mg/kg or 10ml/L or 10 ppm unless the medicine is administered by inhalation.
3071	LOBELIA POWDER	A, H	The concentration in the medicine must be no more than 0.001% or

			10mg/kg or 10ml/L or 10 ppm unless the medicine is administered by inhalation.
3072	LOLIUM PERENNE	A, H	
3073	LOLIUM TEMULENTUM	A, H	
3074	LONGIFOLENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total longifolene concentration in a medicine must be no more than 1%.
3075	LONICERA CAPRIFOLIUM	A, E, H	
3076	LONICERA JAPONICA	A, E, H	
3077	LONICERA PERICLYMENUM	A, H	
3078	LOPHATHERUM GRACILE	A, H	
3079	LOQUAT	E	
3080	LORANTHUS PARASITICUS	A, H	
3081	LOROPETALUM CHINENSE	A, H	
3082	LOTUS CORNICULATUS	A, H	
3083	LOVAGE OIL	A, E, H	
3084	LOVAGE ROOT DRY	A, H	
3085	LOVAGE ROOT POWDER	A, H	
3086	LUDWIGIA PROSTRATA	A, H	
3087	LUFFA CYLINDRICA	A, H	
3088	LUFFA PURGANS	A, H	
3089	LUTEIN	A, E, H	When used as an excipient, permitted for use only as a colour in medicines limited to topical and oral routes of administration.
3090	LYCHEE	E	
3091	LYCIUM BARBARUM	A, H	
3092	LYCIUM CHINENSE	A, E, H	
3093	LYCOPENE	A, E	
3094	LYCOPERSICON ESCULENTUM	A, E, H	Steroidal alkaloids calculated as solanine is a mandatory component of Lycopersicon

			esculentum. The maximum daily dose must not provide more than 10 mg of steroidal alkaloids calculated as solanine.
3095	LYCOPODIUM ANNOTINUM	A, H	
3096	LYCOPODIUM CLAVATUM	A, H	
3097	LYCOPODIUM COMPLANATUM	A, H	
3098	LYCOPUS EUROPAEUS	A, H	
3099	LYCOPUS LUCIDUS	A, H	
3100	LYCOPUS VIRGINICUS	A, H	Pulegone is a mandatory component of Lycopus virginicus. The concentration of pulegone in the medicine must be no more than 4%.
3101	LYGODIUM JAPONICUM	A, H	
3102	LYSIMACHIA CHRISTINAE	A, H	
3103	LYSIMACHIA VULGARIS	A, H	
3104	LYSINE	A, E	
3105	LYSINE HYDROCHLORIDE	A, E	
3106	LYTHRUM HYSSOPIFOLIA	A, H	
3107	LYTHRUM SALICARIA	A, H	
3108	LYTHRUM VERTICILLATUM	A, H	
3109	MACADAMIA INTEGRIFOLIA	A, E	
3110	MACADAMIA NUT OIL	E	
3111	MACADAMIA TERNIFOLIA	A, E, H	
3112	MACE	E	Safrole is a mandatory component of Mace. When used internally, the concentration of safrole in the medicine must be no more than 0.1%. When used topically, the concentration of safrole in the medicine must be no more than 1.0%.
3113	MACE OIL	A, H	Safrole is a mandatory component of Mace oil.

			When used internally, the concentration of safrole in the medicine must be no more than 0.1%. When used topically, the concentration of safrole in the medicine must be no more than 1.0%. When the concentration of mace oil in the preparation is more than 50% and the nominal capacity of the container is 25 mL or less, a restricted flow insert must be fitted on the container.
3114	MACROCYSTIS PYRIFERA	A, E, H	Iodine is a mandatory component of Macrocystis pyrifera. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
3115	MACROGOL 1000	E	
3116	MACROGOL 1450	E	Only for use in topical medicines for dermal application.
3117	MACROGOL 1500	E	
3118	MACROGOL 1500 CASTOR OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 2%.
3119	MACROGOL 200	E	Only for use in topical medicines for dermal application.

Volume 4

3120	MACROGOL 20000	E	
3121	MACROGOL 300	E	
3122	MACROGOL 3000	E	
3123	MACROGOL 3350	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing form time to time.
3124	MACROGOL 40	E	Only for use in topical medicines for dermal application.
3125	MACROGOL 400	E	
3126	MACROGOL 4000	E	
3127	MACROGOL 45000	E	Only for use in topical medicines for dermal application.
3128	MACROGOL 600	E	
3129	MACROGOL 6000	E	
3130	MACROGOL 600000	E	
3131	MACROGOL 800	E	
3132	MACROGOL 8000	E	
3133	MACROGOL 900	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.95%.
3134	MACROGOL POLY(VINYL ALCOHOL) GRAFTED POLYMER	E	Only for use in oral medicines. The concentration in the medicine must be no more than 5%.
3135	MACROPIPER EXCELSUM VAR EXCELSUM	A, H	
3136	MAGNESIUM AMINO ACID	A, E, H	Only for use in oral medicines.

	CHELATE		The concentration of magnesium must be no more than 25% of the magnesium amino acid chelate.
3137	MAGNESIUM ASCORBATE	A, E, H	
3138	MAGNESIUM ASCORBATE MONOHYDRATE	A, E, H	
3139	MAGNESIUM ASCORBYL PHOSPHATE	E	Only for use in topical medicines for dermal application.
3140	MAGNESIUM ASPARTATE	A, E, H	
3141	MAGNESIUM ASPARTATE DIHYDRATE	A, E, H	
3142	MAGNESIUM ASPARTATE TETRAHYDRATE	A, E, H	
3143	MAGNESIUM CARBONATE HYDRATE	A, E, H	
3144	MAGNESIUM CHLORIDE 4.5-HYDRATE	A	Magnesium is a mandatory component of magnesium chloride 4.5-hydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium,

			which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3145	MAGNESIUM CHLORIDE HEXAHYDRATE	A, E, H	Magnesium is a mandatory component of magnesium chloride hexahydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3146	MAGNESIUM CITRATE	A, E, H	
3147	MAGNESIUM CITRATE NONAHYDRATE	A, E, H	

3148	MAGNESIUM CITRATE TETRADECAHYDRATE	A, E, H	
3149	MAGNESIUM DIGLUTAMATE	A, E, H	
3150	MAGNESIUM GLUCONATE	A, E, H	
3151	MAGNESIUM GLYCEROPHOSPHATE	A, E, H	
3152	MAGNESIUM GLYCINATE	A	Only for use in oral medicines.
3153	MAGNESIUM GLYCINATE DIHYDRATE	A	Only for use in oral medicines. Magnesium is a mandatory component of Magnesium glycinate dihydrate. The percentage of Magnesium from Magnesium glycinate dihydrate should be calculated based on the molecular weight of Magnesium glycinate dihydrate.
3154	MAGNESIUM HYDROGEN PHOSPHATE	H	Magnesium is a mandatory component of magnesium hydrogen phosphate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label:

			- (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3155	MAGNESIUM HYDROXIDE	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time. Magnesium is a mandatory component of magnesium hydroxide. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect

			or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3156	MAGNESIUM LYSINATE	A	Only for use in oral medicines.
3157	MAGNESIUM METHIONINATE	A	Only for use in oral medicines.
3158	MAGNESIUM NITRATE	E	Only for use in topical medicines for dermal application.
3159	MAGNESIUM OROTATE	A, E, H	
3160	MAGNESIUM OROTATE DIHYDRATE	A, E, H	
3161	MAGNESIUM OXIDE	A, E, H	Magnesium is a mandatory component of magnesium oxide. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect

			or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3162	MAGNESIUM PHOSPHATE PENTAHYDRATE	A, E, H	Magnesium is a mandatory component of magnesium phosphate pentahydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3163	MAGNESIUM PHOSPHATE TRIBASIC	A, E, H	Magnesium is a mandatory component of magnesium phosphate tribasic. The percentage of magnesium

			from magnesium phosphate tribasic should be calculated based on the molecular weight of magnesium phosphate tribasic. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3164	MAGNESIUM PYRUVATE	A	Only for use in oral medicines. The maximum recommended daily dose must be no more than 7 grams.
3165	MAGNESIUM STEARATE	E	
3166	MAGNESIUM SULFATE DIHYDRATE	A, E, H	When used internally, the maximum recommended daily dose must not be more than 1.5g.

			Magnesium is a mandatory component of magnesium sulfate dihydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3167	MAGNESIUM SULFATE HEPTAHYDRATE	A, E, H	When used internally, the maximum recommended daily dose must not be more than 1.5 g. Magnesium is a mandatory component of magnesium sulfate heptahydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or

			related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3168	MAGNESIUM SULFATE MONOHYDRATE	A, E, H	When used internally, the maximum recommended daily dose must not be more than 1.5 g. Magnesium is a mandatory component of magnesium sulfate monohydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts;

			(ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3169	MAGNESIUM SULFATE TRIHYDRATE	A, E, H	When used internally, the maximum recommended daily dose must not be more than 1.5 g. Magnesium is a mandatory component of magnesium sulfate trihydrate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts;

			the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
3170	MAGNESIUM TRISILICATE	E	Magnesium is a mandatory component of magnesium trisilicate. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts; (ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.

Volume 4

3171	MAGNOLIA GLAUCA	A, H	
3172	MAGNOLIA LILIFLORA	A, H	
3173	MAGNOLIA OBOVATA	A, H	
3174	MAGNOLIA OFFICINALIS	A, E, H	
3175	MAGNOLIA SALICIFOLIA	A, H	
3176	MAIZE OIL	A, E, H	
3177	MAIZE STARCH	A, E, H	
3178	MALACHITE GREEN	E	Permitted for use only as a colour for topical use.
3179	MALIC ACID	E	Sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished medicine is safe for its intended purpose.
3180	MALPIGHIA GLABRA	A, E, H	
3181	MALT EXTRACT	E	
3182	MALTITOL	E	
3183	MALTITOL SOLUTION	E	
3184	MALTODEXTRIN	E	Gluten is a mandatory component of Maltodextrin where the ingredient is derived from gluten containing grains such as wheat, barley, rye and oats.
3185	MALTOL	E	
3186	MALTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3187	MALTOSE	E	
3188	MALUS DOMESTICA	A, E, H	The concentration of amygdalin in the medicine must be no more than 0%.

3189	MALUS SYLVESTRIS	A, H	
3190	MALVA MOSCHATA	A, H	
3191	MALVA SYLVESTRIS	A, E, H	
3192	MALVA VERTICILLATA	A, H	
3193	MANDARIN	E	
3194	MANDARIN OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3195	MANDARIN OIL COLDPRESSED	A, E, H	When used internally, oxedrine is a mandatory component of mandarin oil coldpressed. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
3196	MANDARIN OIL TERPENES	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3197	MANDARIN RESIDUE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Volume 4

			flavour concentration in a medicine must be no more than 5%.
3198	MANDARINAL 32048	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3199	MANDRAGORA OFFICINARUM	A, H	Atropine, hyoscine and hyoscyamine are mandatory components of Mandragora officinarum. The concentration in the medicine must be no more than 10 mg/kg or 10 mL/L or 0.001%. The concentration of atropine in the medicine must be no more than 100 micrograms/kg or 100 micrograms/L or 0.00001%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%. The concentration of hyoscyamine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
3200	MANGANESE	H	Only for use as an active homoeopathic ingredient.
3201	MANGANESE (II) DIASPARTATE	A, H	Only for use in oral medicines.
3202	MANGANESE (II) GLYCINATE	A, H	Only for use in oral medicines.
3203	MANGANESE ACETATE TETRAHYDRATE	H	Only for use as an active homoeopathic ingredient.
3204	MANGANESE AMINO ACID	A, E, H	Only for use in oral medicines.

	CHELATE		The concentration of Manganese must be no more than 25% of the manganese amino acid chelate.
3205	MANGANESE CHLORIDE TETRAHYDRATE	A, E, H	
3206	MANGANESE DIASPARTATE	A, E, H	Only for use in oral medicines.
3207	MANGANESE GLUCONATE	A, E, H	
3208	MANGANESE GLYCEROPHOSPHATE	A, E, H	
3209	MANGANESE OXIDE	A, E, H	
3210	MANGANESE SULFATE MONOHYDRATE	A, E, H	
3211	MANGANESE SULFATE TETRAHYDRATE	A, E, H	
3212	MANGIFERA INDICA	A, E, H	
3213	MANGO	E, H	
3214	MANIHOT ESCULENTA	A, H	
3215	MANNITOL	E	
3216	MARANTA ARUNDINACEA	A, H	
3217	MARINE SPONGE	H	Only for use as an active homoeopathic ingredient.
3218	MARJORAM OIL SPANISH	A, E, H	When the concentration in the preparation is more than 50%, the nominal capacity of the container must be no more than 50 mL, the medicine must have a restricted flow insert fitted to the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
3219	MARJORAM OIL SWEET	A, E, H	When the concentration in the preparation is more than 50%, the nominal capacity of the container must be no more than 50 mL, the medicine must have a restricted flow insert fitted to the container

Volume 4

			and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
3220	MARRUBIUM VULGARE	A, E, H	
3221	MARSDENIA CUNDURANGO	A, H	
3222	MARSHMALLOW ROOT DRY	A, H	
3223	MARSHMALLOW ROOT POWDER	A, H	
3224	MASSOIA LACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3225	MASTIC	A, H	
3226	MATE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3227	MATRICARIA CHAMOMILLA	A, E, H	
3228	MATRICARIA FLOWER DRY	A, E, H	
3229	MEADOWSWEET HERB DRY	A, H	Methyl salicylate is a mandatory component of meadowsweet herb dry. Not to be included in medicines for use in the eye or on damaged skin. When used internally, the concentration of methyl salicylate in the medicine must not be more

	than 0.001%. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish. The following warning statement is required on the medicine label: - (METSAL) 'Contains methyl salicylate' (or words to that effect). When for use in topical medicines for dermal application i) the concentration of methyl salicylate in the medicine must not be more than 25% ii) the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight.'

			(or words to that effect); - (AVOID) 'Avoid prolonged exposure in the sun' (or words to that effect); iii) if the concentration of methyl salicylate in the medicine is greater than 1%, the following warning statement is required on the medicine label: - (IRRIT) 'If irritation develops, discontinue use'.
3230	MECOBALAMIN	A	Only for use in oral medicines.
3231	MEDICAGO SATIVA	A, E, H	The level of l-canavanine must be no more than that of the dried leaf. When fresh leaf extract is used and the extraction ratio is between 34:1 and 46:1, the quantity of l-canavanine in the extract must not be more than that in the fresh leaf.
3232	MEDIUM CHAIN TRIGLYCERIDES	E	
3233	MELALEUCA ALTERNIFOLIA	A, E, H	Cineole is a mandatory component of Melaleuca alternifolia. In liquid preparations when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the

			concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
3234	MELALEUCA CAJUPUTI	A, E, H	Cineole is a mandatory component of Melaleuca cajuputi. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
3235	MELALEUCA CITRINA	A, H	
3236	MELALEUCA DISSITIFLORA	A, H	Cineole is a mandatory component of Melaleuca dissitiflora. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%:

			a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
3237	MELALEUCA ERICIFOLIA	A, E, H	Cineole is a mandatory component of Melaleuca ericifolia. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%

			and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
3238	MELALEUCA LINARIIFOLIA	A, H	Cineole is a mandatory component of Melaleuca linariifolia. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
3239	MELALEUCA OIL	A, E, H	Cineole and cajuput oil are a mandatory components of Melaleuca Oil. When the plant preparation is oil and the concentration in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL and the medicine requires the following warning statements on

			the medicine label: - (CHILD) ‘Keep out of reach of children’ (or word to that effect) - (NTAKEN) ‘Not to be taken’. When the nominal capacity of the container is 15 mL or less, then a restricted flow insert must be fitted on the container. Where the nominal capacity of the container is more than 15 mL but less than or equal to 25 mL, then a child resistant closure and restricted flow insert must be fitted on the container.
3240	MELALEUCA QUINQUENERVIA	A, E, H	Cineole is a mandatory component of Melaleuca quinquenervia. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25%: a) the nominal capacity of the container must be no more than 25 millilitres; b) a restricted flow insert must be fitted on the container; and c) the container must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In liquid preparations, when the concentration of cineole OR the concentration of oil or distillate in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres the medicine must also have a child resistant closure.
3241	MELICOPE PTELEIFOLIA	A, H	

3242	MELILOTUS OFFICINALIS	A, E, H	Coumarin is a mandatory component of Melilotus officinalis. The concentration of coumarin in the medicine must be no more than 0.001%.
3243	MELISSA OFFICINALIS	A, E, H	
3244	MELON	E	
3245	MENADIONE SODIUM BISULFITE	E	
3246	MENAQUINONE 7	A	For oral use only. The medicine must not provide more than 180 micrograms per maximum daily dose in adults, 90 micrograms per maximum daily dose in children between 10-18 years, and 45 micrograms per maximum daily dose in children less than 10 years of age.
3247	MENISPERMUM CANADENSE	A, H	
3248	MENTHA AQUATICA	A, H	Menthol is a mandatory component of Mentha aquatica. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required

Volume 4

			on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3249	MENTHA ARVENSIS	A, E, H	Menthol is a mandatory component of Mentha arvensis. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive

			skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3250	MENTHA ARVENSIS LEAF OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must be no more than 5%. The total fragrance proprietary excipient formulation in a medicine must be no more 1%. Menthol is a mandatory component of Mentha arvensis leaf oil. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

			(iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3251	MENTHA ARVENSIS OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%. Menthol is a mandatory component of Mentha arvensis oil. When the medicine is for topical use for dermal application: (i) the medicine must not be

			intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statements is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3252	MENTHA HAPLOCALYX	A, E, H	Menthol is a mandatory component of Mentha haplocalyx. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin;

			(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3253	MENTHA PULEGIUM	A, H	D-pulegone, menthol and volatile oil components (of Mentha pulegium) are mandatory components of Mentha pulegium. When the nominal capacity of the container is more than 15 millilitres, the concentration of d-pulegone in the medicine must be no more than 4%.

	When the concentration of d-pulegone in the preparation is more than 4% and the nominal capacity of the container is 15 millilitres or less, the medicine must have a child resistant closure and restricted flow insert fitted on the container. The medicine requires the following warning statements on the medicine label: - (NTAKEN) 'Not to be taken'; - (CHILD) 'Keep out of reach of children' (or words to that effect). When the medicine is for topical use for dermal application: a) the maximum recommended daily dose must not contain more than 150 mg of Mentha pulegium oil or distillate; b) the medicine must not be intended for use in the eye or on damaged skin; c) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; d) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). e) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use.

Volume 4

			f) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use: a) the maximum recommended daily dose must not contain more than 50 mg of Mentha pulegium oil or distillate; b) the maximum recommended daily dose must not contain more than 1 gram of menthol.
3254	MENTHA SPICATA	A, E, H	Menthol is a mandatory component of Mentha spicata. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a

			large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3255	MENTHA X CARDIACA	A, E, H	Menthol is a mandatory component of Mentha x cardiaca. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops,

			discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3256	MENTHA X PIPERITA	A, E, H	Menthol is a mandatory component of Mentha x piperita. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more

			than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3257	MENTHADIENYL ACETATE	E	Menthadienyl acetate must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of the flavour proprietary excipient formulation containing menthadienyl acetate must not be more than 5% of the total medicine.
3258	MENTHANYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3259	MENTHOFURAN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3260	MENTHOL	A, E	When the medicine is for topical use for dermal application: (i) the medicine must not be

Volume 4

			intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label: - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3261	MENTHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3262	MENTHONE GLYCERINE ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3263	MENTHONE THIOL FRACTION	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3264	MENTHOXYPROPANEDIOL	E	For oral use only. The concentration in the medicine must be no more than 0.04%.
3265	MENTHYL 2-HYDROXYETHYL CARBONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3266	MENTHYL 2-HYDROXYPROPYL CARBONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3267	MENTHYL ANTHRANILATE	A	Only for use in topical medicines for dermal application and not to be included in medicines intended

Volume 4

			for use in the eye. The concentration in the medicine must not be more than 5%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3268	MENTHYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3269	MENTHYL LACTATE	E	
3270	MENYANTHES TRIFOLIATA	A, H	
3271	MERCURIC CHLORIDE	H	Only for use as an active homoeopathic ingredient. Mercury is a mandatory component of mercuric chloride. The total concentration of mercury in the medicine must not be more than 1 mg/kg or 1 mg/L or 0.0001%.
3272	MERCURY	H	Only for use as an active homoeopathic ingredient. The total concentration of mercury in the medicine must not be more than 1 mg/kg or 1 mg/L or 0.0001%.
3273	METACRESOL	E	Only for use in topical medicines for dermal application.

3274	METHACRYLIC ACID COPOLYMER	E	Only for use in oral medicines.
3275	METHANOL	E	The residual solvent limit is 30 mg per recommended daily dose. The concentration in the medicine must be no more than 0.3%.
3276	METHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
3277	METHIONINE	A, E	
3278	METHYL 2,6,6-TRIMETHYLCYCLOHEX-2-ENE-1-CARBOXYLATE	E	Only for use in medicines in combination with other permitted ingredients as a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must not be more than 1%.
3279	METHYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3280	METHYL 2-OCTYNOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Volume 4

			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3281	METHYL 3,6-DIMETHYLRESORCYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3282	METHYL ACETATE	E	The residual solvent limit is 50 mg per recommended daily dose. The concentration in the medicine must be no more than 0.5%.
3283	METHYL ACETOPHENONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3284	METHYL ACETYL RICINOLEATE	E	Only for use in topical medicines for dermal application.
3285	METHYL ANISATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3286	METHYL ANTHRANILATE	E	Permitted for use only in

			combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3287	METHYL BENZOATE	E	Only for use in topical medicines for dermal application.
3288	METHYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3289	METHYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3290	METHYL CAPRYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3291	METHYL CARBITOL	E	Permitted for use only in

			combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3292	METHYL CEDRYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3293	METHYL CHAVICOL	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The ingredient is not to be included in medicines intended for oral use. The quantity of methyl chavicol in a medicine must be no more than 0.01%. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
3294	METHYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3295	METHYL CIS-5-OCTENOATE	E	Permitted for use only in combination with other permitted

			ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3296	METHYL CYCLOPENTENOLONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3297	METHYL CYCLOPENTYLIDENEACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3298	METHYL DI-TERT-BUTYL-4-HYDROXYHYDROCINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3299	METHYL DIHYDROABIETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3300	METHYL DIISOPROPYL	E	Permitted for use only in

Volume 4

	PROPIONAMIDE		combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3301	METHYL ETHER	E	Only for use in topical medicines for dermal application.
3302	METHYL ETHYL KETONE	E	The residual solvent limit is 50 mg per maximum recommended daily dose. The concentration in the medicine must be no more than 0.5%.
3303	METHYL EUGENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3304	METHYL FUROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3305	METHYL GLUCETH-10	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%. Residue levels of ethylene oxide

			are to be kept below the level of detection.
3306	METHYL GLUCETH-20	E	Only for use in topical medicines for dermal application.
3307	METHYL GLUCETH-20 BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3308	METHYL GLUCETH-20 SESQUIHYDRATE	E	Only for use in topical medicines for dermal application.
3309	METHYL GLUCOSE DIOLEATE	E	Only for use in topical medicines for dermal application.
3310	METHYL GLUCOSE SESQUIOLEATE	E	Only for use in topical medicines for dermal application.
3311	METHYL GLUCOSE SESQUISTEARATE	E	Only for use in topical medicines for dermal application.
3312	METHYL HEPTANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%.
3313	METHYL HEPTENONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Volume 4

			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3314	METHYL HEPTYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3315	METHYL HEXYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3316	METHYL HEXYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3317	METHYL HYDROGENATED ROSINATE	E	Only for use in topical medicines for dermal application.
3318	METHYL HYDROJASMONATE	E	Only for use in topical medicines for dermal application.
3319	METHYL HYDROXYBENZOATE	E	

3320	METHYL IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3321	METHYL ISOBUTYL KETONE	E	The residual solvent limit is 50 mg per maximum daily dose. The concentration in the medicine must be no more than 0.5%.
3322	METHYL ISOEUGENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3323	METHYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3324	METHYL JASMONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than

Volume 4

			5%.
3325	METHYL LAURATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
3326	METHYL LINOLEATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3327	METHYL LINOLENATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3328	METHYL MAGNESIUM CHLORIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3329	METHYL METHACRYLATE CROSSPOLYMER	E	Methyl methacrylate is a mandatory component of methyl methacrylate crosspolymer. Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. When the concentration of methyl methacrylate crosspolymer is greater than 1%, the medicine

			must not be intended for use on damaged skin. The total concentration of methyl methacrylate crosspolymer in the medicine must not be more than 4.85%. The total concentration of methyl methacrylate as residual monomer in the medicine must not be more than 1%.
3330	METHYL METHOXY PYRAZINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3331	METHYL MYRISTATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3332	METHYL NAPHTHYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3333	METHYL NONYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Volume 4

			fragrance concentration in a medicine must be no more 1%.
3334	METHYL NONYLENATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3335	METHYL OCTIN CARBONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3336	METHYL PALMITATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3337	METHYL PHENYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3338	METHYL PHENYL CARBINYL-	E	Permitted for use only in

	ISO-BUTYRATE		combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3339	METHYL PHENYL GLYCIDATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3340	METHYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3341	METHYL PHENYLCARBINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3342	METHYL ROSINATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Volume 4

			medicine must be no more than 1%.
3343	METHYL SALICYLATE	A, E	Not to be included in medicines for use in the eye or on damaged skin. When used internally, the concentration in the medicine must not be more than 0.001%. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish. The following warning statement is required on the medicine label: - (METSAL) 'Contains methyl salicylate' (or words to that effect). When for use in topical medicines for dermal application: i) the concentration of methyl salicylate in the medicine must not be more than 25%; ii) the following warning statements are required on the medicine label:

			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect); - (AVOID) 'Avoid prolonged exposure in the sun' (or words to that effect); iii) if the concentration of methyl salicylate in the medicine is greater than 1%, the following warning statement is required on the medicine label: - (IRRIT) 'If irritation develops, discontinue use'.
3344	METHYL STEARATE	E	
3345	METHYL THIOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3346	METHYL TRIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
3347	METHYL-3-METHYLTHIOPROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Volume 4

3348	METHYL-BETA-METHYL THIOLPROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3349	METHYL-PARA-TERT-BUTYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3350	METHYLBENZYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3351	METHYLCELLULOSE	A, E	
3352	METHYLCHLOROISOTHIAZOLINONE	E	Only for use in topical medicines for dermal application that are rinsed off the skin. The total concentration of methylchloroisothiazolinone and methylisothiazolinone in the medicine must be no more than 0.0015%.
3353	METHYLCYCLOHEXADIENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

3354	METHYLENE BIS-BENZOTRIAZOLYL TETRAMETHYLBUTYLPHENOL	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 10%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3355	METHYLISOTHIAZOLINONE	E	Only for use in topical medicines for dermal application that are rinsed off the skin. The total concentration of methylchloroisothiazolinone and methylisothiazolinone in the medicine must be no more than 0.0015%.
3356	METHYLMERCAPTAN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3357	METHYLPROPANEDIOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.

Volume 4

3358	METHYLSILANOL/SILICATE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.1%.
3359	METHYLSTYRENE/VINYLTOLUENE COPOLYMER	E	Only for use in topical medicines for dermal application.
3360	MICA	E	Only for use when the route of administration is oral, dental or topical. The concentration in oral medicines must be no more than 2.5%. The concentration in dental toothpastes must be no more than 0.5%.
3361	MICROCALICIUM ARENARIUM	A, H	
3362	MICROCOCCUS LUTEUS LYSATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.005%.
3363	MICROCOS PANICULATA	A, H	
3364	MICROCRYSTALLINE CELLULOSE	E	
3365	MICROCRYSTALLINE WAX	E	Only for use as an excipient in medicines for topical, oral or oral application routes of administration. When microcrystalline wax is used as an excipient ingredient, the route of administration 'oral' is only permitted when the dosage form is 'chewing gum'.
3366	MILK FAT	E	Permitted for use only in

			combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3367	MILK THISTLE FRUIT DRY	A, H	
3368	MILK THISTLE FRUIT POWDER	A, H	
3369	MILLET	E	
3370	MILLETTIA DIELSIANA	A, H	
3371	MIMOSA ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3372	MIMULUS GUTTATUS	A, H	
3373	MINT OIL DEMENTHOLISED	A, E, H	Menthol is a mandatory component of mint oil dementholised. When the medicine is for topical use for dermal application: (i) the medicine must not be intended for use in the eye or on damaged skin; (ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use; (iii) the following warning statement is required on the medicine label: - (EYE) Avoid contact with eyes (or words to that effect). (iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

Volume 4

			- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area; - (IRRIT) If irritation develops, discontinue use. (v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label: – (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation. When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3374	MINTLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3375	MITCHELLA REPENS	A, H	
3376	MIXED (HIGH-ALPHA TYPE) TOCOPHEROLS CONCENTRATE	A, E	
3377	MIXED (LOW-ALPHA TYPE) TOCOPHEROLS CONCENTRATE	A, E	
3378	MIXED TERPENES	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3379	MODIFIED FOOD STARCH	E	
3380	MOLASSES	E	Permitted for use only in

			combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3381	MOLYBDENUM	H	Only for use as an active homoeopathic ingredient. When Molybdenum is sourced from Molybdenum trioxide then the maximum daily dose must be no more than 125 micrograms. When Molybdenum is sourced from yeast - high molybdenum then the maximum recommended daily dose must be no more than 62.5 micrograms.
3382	MOLYBDENUM TRIOXIDE	A	Molybdenum is a mandatory component of Molybdenum trioxide. The maximum daily dose of molybdenum from Molybdenum trioxide must be no more than 125 micrograms. The percentage of molybdenum from molybdenum trioxide should be calculated based on the molecular weight of molybdenum trioxide.
3383	MOMORDICA BALSAMINA	A, H	
3384	MOMORDICA CHARANTIA	A, H	
3385	MOMORDICA COCHINCHINENSIS	A, H	
3386	MONARDA DIDYMA	A, H	
3387	MONO- AND DI- GLYCERIDES	E	
3388	MONOBASIC AMMONIUM PHOSPHATE	E	Only for use in topical medicines for dermal application.
3389	MONOBASIC CALCIUM PHOSPHATE	A, E, H	

Volume 4

3390	MONOBASIC POTASSIUM PHOSPHATE	A, E, H	When used in a solid medicine containing this ingredient, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid medicine containing this ingredient, the pH of the medicine must be no more than 11.5.
3391	MONOBASIC SODIUM PHOSPHATE	A, E, H	When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
3392	MONOBASIC SODIUM PHOSPHATE DIHYDRATE	E	When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5. When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
3393	MONOETHANOLAMINE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 5%.
3394	MONOMENTHYL GLUTARATE	E	Monomenthyl glutarate must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations containing monomenthyl glutarate must not be more than 5% of the total medicine. The maximum recommended daily dose of the medicine must not provide more than 1.8mg of monomenthyl glutarate.

3395	MONOMENTHYL SUCCINATE	E	Monomenthyl succinate must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of the flavour proprietary excipient formulation containing monomenthyl succinate must not be more than 5% of the total medicine.
3396	MONOPHOSPHOTHIAMINE	A	
3397	MONOPHOSPHOTHIAMINE DIHYDRATE	A	
3398	MONOPOTASSIUM GLUTAMATE	A, E	
3399	MONOSODIUM DIHYDROGEN CITRATE	E	
3400	MONOSODIUM GLUTAMATE MONOHYDRATE	A, E	
3401	MONSTERA DELICIOSA	A, H	
3402	MONTAN WAX	E	
3403	MORDANT RED 11	E	Permitted for use only as a colour for topical use. The concentration in the medicine must be no more than 0.05%..
3404	MORINDA CITRIFOLIA	A, H	Only for use when the plant part is fruit and the plant preparation is fruit juice or fruit powder. Fruit powder must be produced by freeze drying the whole fruit (excluding the seeds).
3405	MORINDA OFFICINALIS	A, H	
3406	MORINGA OLEIFERA	A, H	
3407	MORUS ALBA	A, H	
3408	MORUS BOMBYCIS	A, H	
3409	MORUS NIGRA	A, E, H	

Volume 4

3410	MOSKENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3411	MOTHERWORT HERB DRY	A, H	
3412	MOTHERWORT HERB POWDER	A, H	
3413	MUCUNA PRURIENS	A	Levodopa is a mandatory component of Mucuna pruriens. The concentration of levodopa in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.
3414	MULBERRY	E	
3415	MUNG BEAN	E	
3416	MURRAYA KOENIGII	A, H	
3417	MURRAYA PANICULATA	A, H	
3418	MUSA X PARADISIACA	A, H	
3419	MUSK KETONE	E	Only for use in topical medicines for dermal application.
3420	MUSK TIBETENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3421	MUSK XYLOL	E	Only for use in topical medicines for dermal application.
3422	MUSKS	H	Only for use as an active homoeopathic ingredient.
3423	MUSTARD	E	Allyl isothiocyanate is a mandatory component of mustard when the plant part is seed.

			The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
3424	MUSTARD OIL	E	Allyl isothiocyanate is a mandatory component of mustard oil when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
3425	MUSTARD SEED OIL	E	Allyl isothiocyanate is a mandatory component of mustard seed oil when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
3426	MYOSOTIS ARVENSIS	A, H	
3427	MYRCENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3428	MYRCENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Volume 4

			1%.
3429	MYRICA CERIFERA	A, E, H	
3430	MYRISTIC ACID	E	
3431	MYRISTIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3432	MYRISTICA FRAGRANS	A, E, H	Safrole is a mandatory component of Myristica fragrans. When for internal use then the concentration of safrole in the medicine must be no more than 0.1%. When for topical use then the concentration of safrole in the medicine must be no more than 1%. When the plant preparation is oil or distillate and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or word to that effect).
3433	MYRISTYL ALCOHOL	E	Only for use in topical medicines for dermal application.
3434	MYRISTYL LACTATE	E	Only for use in topical medicines for dermal application.

3435	MYRISTYL MYRISTATE	E	Only for use in topical medicines for dermal application.
3436	MYROXYLON BALSAMUM	A, E, H	
3437	MYROXYLON BALSAMUM VAR. PEREIRAE	A, H	
3438	MYRRH	A, H	
3439	MYRRH OIL	A, E, H	
3440	MYRRH RESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3441	MYRRHIS ODORATA	A, H	
3442	MYRSINE AFRICANA	A, H	
3443	MYRTENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3444	MYRTENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3445	MYRTLE ESSENCE MAX	E	Permitted for use only in combination with other permitted ingredients as a fragrance.

Volume 4

			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3446	MYRTLE OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used as a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3447	MYRTUS COMMUNIS	A, E, H	
3448	N,N'-BIS(SALICYLIDENE)PROPYLENEDIAMINE	E	N,N'-Bis(salicylidene)propylenediamine must only be included in medicines when in combination with other permitted ingredients as a proprietary excipient formulation in medicines with a dermal route of administration for topical application.
3449	N-(2-(PYRIDIN-2-YL)ETHYL)-P-MENTHANE-3-CARBOXAMIDE	E	N-(2-(pyridin-2-yl)ethyl)-p-menthane-3-carboxamide must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations containing N-(2-(pyridin-2-yl)ethyl)-p-menthane-3-carboxamide must not be more than 5% of the total medicine. The maximum recommended daily dose of the medicine must not provide more than 90 micrograms of N-(2-(pyridin-2-yl)ethyl)-p-menthane-3-carboxamide.
3450	N-BUTYL SULFIDE	E	Permitted for use only in

			combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3451	N-GLUCONYL ETHANOLAMINE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3452	N-HEXYL 2-BUTENOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3453	N-NONYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3454	NAPHTHALENE	H	Only for use as an active homoeopathic ingredient.
3455	NARDOSTACHYS CHINENSIS	A, H	

Volume 4

3456	NARINGIN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3457	NASTURTIUM OFFICINALE	A, E, H	
3458	NATURAL FISH OIL	A, E	When therapeutic indications for this product are made against Vitamin A or colecalciferol (Vitamin D), they are mandatory components of natural fish oil. When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%. When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents. When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label: - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use. - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.' NOTE: Position this warning at

			the beginning of the directions for use. - (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.' When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.
3459	NAUCLEA OFFICINALIS	A, H	
3460	NELUMBO NUCIFERA	A, H	
3461	NELUMBO NUCIFERA FLOWER WAX	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.1%.
3462	NEOHESPERIDIN-DIHYDROCHALCONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.1%
3463	NEOMENTHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3464	NEOPENTYL GLYCOL DIHEPTANOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Volume 4

			The concentration in the medicine must be no more than 25%.
3465	NEOPENTYL GLYCOL DIISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
3466	NEOPENTYL GLYCOL DIOCTANOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 8.1%. When the concentration of neopentyl glycol dioctanoate is greater than 5%, the medicine must not be intended for use on damaged skin.
3467	NEOPENTYL GLYCOL DIOCTANOATE/DIDECANOATE	E	Only for use in topical medicines for dermal application.
3468	NEOPICRORHIZA SCROPHULARIIFLORA	A, H	
3469	NEPETA CATARIA	A, H	Pulegone is a mandatory component of Nepeta cataria and must be declared in the application. The concentration of pulegone in the medicine must be no more than 4%.
3470	NERAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

3471	NERIUM OLEANDER	A, H	The concentration of equivalent dry Nerium oleander in the product must be no more than 1mg/Kg or 1mg/L or 0.0001%.
3472	NEROL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3473	NEROL OXIDE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
3474	NEROLIDOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3475	NERONE	E	Permitted for use only in

Volume 4

			combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
3476	NERYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3477	NERYL-ISO-BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3478	NICKEL	H	Only for use as an active homoeopathic ingredient.
3479	NICOTIANA TABACUM	H	Only for use as an active homoeopathic ingredient.
3480	NICOTINAMIDE	A, E, H	
3481	NICOTINAMIDE ASCORBATE	A, E	
3482	NICOTINAMIDE RIBOSIDE CHLORIDE	A	Ribose is a mandatory component of nicotinamide riboside chloride. Only permitted for use in medicines limited to oral routes of administration. The maximum recommended daily dose of the medicine must

			not provide more than 300 mg of nicotinamide riboside chloride. The following warning statement (or words to the same effect) is required on the medicine label: - (NTAKEN12) 'Not to be taken by children under 12 years old.' When the maximum recommended daily dose of the medicine provides greater than 230 mg of nicotinamide riboside chloride, the following warning statement is required on the medicine label: - (PREG) 'Not recommended for use during pregnancy or lactation'.
3483	NICOTINIC ACID	A, E	The medicine must contain no more than 100 mg of nicotinic acid per dosage unit.
3484	NIGELLA DAMASCENA	A, H	
3485	NIGELLA SATIVA	A, E, H	
3486	NITRIC ACID	E, H	The concentration of nitric acid in the medicine must be no more than 0.5%.
3487	NONADIENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3488	NONANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Volume 4

			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3489	NONANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3490	NONFAT DRY MILK	E, H	
3491	NONIVAMIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3492	NONOXINOL 10	E	Only for use in topical medicines for dermal application.
3493	NONOXINOL 12	E	For use in hand scrub formulations for healthcare professionals only. Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
3494	NONOXINOL 5	E	Permitted for use only in combination with other permitted

			ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3495	NONOXINOL 9	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 25%.
3496	NONYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3497	NOOTKATONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3498	NOPYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3499	NORDIHYDROGUAIARETIC ACID	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.3%.
3500	NOTOPTERYGIUM FORBESII	A, H	

Volume 4

3501	NOTOPTERYGIUM INCISIUM	A, H	
3502	NUPHAR JAPONICA	A, H	
3503	NUPHAR LUTEA	A, H	
3504	NUTMEG DRY	A, E, H	Safrole is a mandatory component of Nutmeg Dry. When for internal use then the concentration of safrole from all ingredients in the medicine must be no more than 0.1%. When for topical use then the concentration of safrole from all ingredients in the medicine must be no more than 1%.
3505	NUTMEG OIL	A, E, H	Safrole is a mandatory component of Nutmeg oil. When for internal use then the concentration of safrole in the medicine must be no more than 0.1%. When for topical use then the concentration of safrole in the medicine must be no more than 1%. When the concentration of Nutmeg oil in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, the medicine must have a restricted flow insert fitted on the container and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
3506	NUTMEG POWDER	A, E, H	Safrole is a mandatory component of Nutmeg powder. When for internal use then the concentration of safrole in the medicine must be no more than 0.1%. When for topical use then the concentration of safrole in the

			medicine must be no more than 1%.
3507	NUX VOMICA DRY	A, H	Strychnine (of Strychnos spp.) is a mandatory component of Nux Vomica Dry. The concentration of in the medicine must be no more than 1mg/Kg or 1mg/L or 0.0001%.
3508	NUX VOMICA POWDER	H	Only for use as an active homoeopathic ingredient. Strychnine (of Strychnos spp.) is a mandatory component of Nux vomica powder. The concentration in the medicine must be no more than 1mg/Kg or 1mg/L or 0.0001%.
3509	NYCTANTHES ARBOR-TRISTIS	A, H	When the plant part is leaf: a) methyl salicylate is a mandatory component of Nyctanthes arbor-tristis; b) not to be included in medicines for use in the eye or on damaged skin; c) when used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%; d) when the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging; e) when the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way

			that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish; f) the following warning statement is required on the medicine label: - (METSAL) ‘Contains methyl salicylate’ (or words to that effect); and g) when for use in topical medicines for dermal application: i) the concentration of methyl salicylate in the medicine must not be more than 25% ii) the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect); - (AVOID) 'Avoid prolonged exposure in the sun' (or words to that effect); iii) if the concentration of methyl salicylate in the medicine is greater than 1%, the following warning statement is required on the medicine label: - (IRRIT) 'If irritation develops, discontinue use'.
3510	NYLON	E	Only for use in topical medicines for dermal application.

3511	NYLON 6/12	E	Only for use in topical medicines for dermal application.
3512	NYLON-12	E	Only for use in topical medicines for dermal application.
3513	NYMPHAEA ALBA	A, E, H	
3514	NYMPHAEA CAERULEA	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine to be no more than 0.3%. Only for use in liquid extracts where the plant part is the flower and the solvent in 100% water.
3515	NYMPHAEA ODORATA	A, H	
3516	OAK CHIPS EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3517	OAKMOSS ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3518	OAT	E, H	Only for use as an active homoeopathic or excipient ingredient.

Volume 4

			Gluten is a mandatory component of Oat when the route of administration is other than topical and mucosal.
3519	OAT BRAN	E	Gluten is a mandatory component of Oat bran when the route of administration is other than topical and mucosal.
3520	OATMEAL COLLOIDAL	A, E	Gluten is a mandatory component of Oatmeal colloidal when the route of administration is other than topical and mucosal.
3521	OCIMENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3522	OCIMENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3523	OCIMUM BASILICUM	A, E, H	When the plant preparation is oil or distillate, Methyl chavicol, eugenol, methyleugenol and cineole are mandatory components of Ocimum basilicum.

	The concentration of methyleugenol in the medicine must not exceed 1%. When the concentration of Methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25 millilitres. When the concentration of Methyl chavicol in the medicine is more than 5% and the nominal capacity of the container is 25 millilitres or less, a restricted flow insert must be fitted on the container, and requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect). When the concentration of cineole OR eugenol in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres and the following warning statements must be included on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When the concentration of cineole OR eugenol in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container. When the concentration of cineole OR eugenol in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted

			flow insert fitted on the container. When the preparation is for topical use in the mouth, the preparation may not contain more than 5 millilitres of eugenol and the concentration of eugenol in the product must not be greater than 25%.
3524	OCIMUM KILIMANDSCHARICUM	A, H	Camphor is a mandatory component of Ocimum kilimandscharicum. In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%. In liquid preparations, the nominal capacity of the container must be no more than 25 millilitres. In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%. In essential oil or distillate preparations when the concentration of camphor is more than 2.5%, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. In essential oil or distillate preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must also have a child resistant closure fitted on the container.

3525	OCIMUM MINIMUM	A, H	
3526	OCIMUM TENUIFLORUM	A, H	When the plant part is oil or distillate, eugenol is a mandatory component of Ocimum tenuiflorum. When the concentration of eugenol in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres and the following warning statements must be included on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'. When the concentration of eugenol in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container. When the concentration of eugenol in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container. When the preparation is for topical use in the mouth, the preparation may not contain more than 5 mL of eugenol and the concentration of eugenol in the product must not be greater than 25%.
3527	OCOTEA ODORIFERA	A, H	Safrole is a mandatory component of Ocotea odorifera. When for internal use then the concentration of safrole in the medicine must be no more than

Volume 4

			0.1%. When for topical use then the concentration of safrole in the medicine must be no more than 1%.
3528	OCTACOSANOL	E	
3529	OCTADECANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3530	OCTADECENE/MA COPOLYMER	E	Only for use in topical medicines for dermal application.
3531	OCTAHYDRO-4,7-METHANO-3AH-INDENE-3A-CARBOXYLIC ACID, ETHYL ESTER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3532	OCTAHYDROCOUMARIN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3533	OCTAN-1-OL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

			flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3534	OCTANAL DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3535	OCTANOHYDROXAMIC ACID	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
3536	OCTANOIC ACID	A, E	When for topical use, the concentration in the medicine must be no more than 2% (w/w). When for excipient use, permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
3537	OCTENE-1	E	Permitted for use only in

			combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
3538	OCTOCRYLENE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 10%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3539	OCTOXINOL 10	E	Only for use in topical medicines for dermal application.
3540	OCTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3541	OCTYL CROTONATE	E	Octyl crotonate must only be included in medicines when in

			combination with other permitted ingredients as a fragrance proprietary excipient formulation. The total concentration of the fragrance proprietary excipient formulation containing octyl crotonate must not be more than 1% of the total medicine.
3542	OCTYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application.
3543	OCTYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3544	OCTYL ISONONANOATE	E	Only for use in topical medicines for dermal application.
3545	OCTYL METHOXYCINNAMATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 10%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3546	OCTYL PALMITATE	E	Only for use in topical medicines

Volume 4

			for dermal application.
3547	OCTYL SALICYLATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 5%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3548	OCTYL STEARATE	E	Only for use in topical medicines for dermal application.
3549	OCTYLBICYCLOHEPTENEDICARBOXIMIDE	E	Only for use in topical medicines for dermal application. The total concentration of octylbicycloheptenedicarboximide in the medicine must not be more than 10%.
3550	OCTYLDODECANOL	E	Only for use in topical medicines for dermal application.
3551	OCTYLDODECETH-25	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%. Residual levels of 1,4-dioxane and ethylene oxide (and related substances) are to be kept below

			the level of detection.
3552	OCTYLDODECYL CITRATE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 12%.
3553	OCTYLDODECYL NEOPENTANOATE	E	Only for use in topical medicines for dermal application.
3554	OCTYLDODECYL STEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%.
3555	OCTYLDODECYL XYLOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1.5%.
3556	OENANTHATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3557	OENANTHE AQUATICA	H	Only for use as an active homoeopathic ingredient. The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.
3558	OENANTHE CROCATA	A, H	The maximum recommended

			daily dose must be no more than 1mg of the equivalent dry herbal material.
3559	OENOTHERA BIENNIS	A, E, H	
3560	OENOTHERA STRICTA	A, H	
3561	OKOUBAKA AUBREVILLEI	A, H	
3562	OLDENLANDIA DIFFUSA	A, E, H	
3563	OLEA EUROPAEA	A, E, H	
3564	OLEIC ACID	E	
3565	OLETH-10	E	Only for use in topical medicines for dermal application.
3566	OLETH-2	E	Only for use in topical medicines for dermal application. Dioxane and Ethylene oxide are mandatory components of Oleth-2. The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%. The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.
3567	OLETH-20	E	Only for use in topical medicines for dermal application.
3568	OLETH-3	E	Only for use in topical medicines for dermal application.
3569	OLETH-3 PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.12%.
3570	OLETH-5	E	Only for use in topical medicines for dermal application.

3571	OLEYL ALCOHOL	E	Only for use in topical medicines for dermal application.
3572	OLIBANUM OIL	A, E, H	
3573	OLIVE OIL	A, E, H	
3574	OMEGA-3 FISH OIL PHYTOSTEROL ESTERS	A	The medicine requires the following warning statement on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women (or words to that effect).'
3575	OMEGA-3-ACID ETHYL ESTERS 60	A	Docosahexaenoic acid, docosapentaenoic acid and eicosapentaenoic acid are mandatory components of omega-3-acid ethyl esters 60. Only permitted for use in medicines that are for oral routes of administration. The maximum recommended daily dose of the medicine must not provide more than 3750 milligrams of docosahexaenoic acid, docosapentaenoic acid and eicosapentaenoic acid combined. The following warning statements are required on the medicine label: - (PREGNT) ‘Not recommended for use by pregnant and lactating women’ (or words to that effect); - (ACOAG) ‘Individuals taking anticoagulants should seek medical advice before taking this product’ (or words to that effect); - (CHILD3) 'Use in children under 12 years is not recommended’; - (FOOD) 'To be taken with food’ (or words to that effect).
3576	OMEGA-3-ACID ETHYL ESTERS 90	A	Only for use in oral medicines. The maximum recommended

			daily dose of the medicine must not provide more than: a) 4000 mg of omega-3-acid ethyl esters 90; and b) 3750 mg EPA, DHA and DPA combined, when used alone or in combination with other sources of omega-3 fatty acids. The following warning statements (or words to the same effect) are required on the medicine label: - (ACOAG) 'Individuals taking anticoagulants should seek medical advice before taking this product.' - (FOOD) 'To be taken with food.' - (PREG) 'Not recommended for use during pregnancy or lactation.' - (CHILD3) 'Use in children under 12 years is not recommended.'
3577	ONION	E	
3578	ONION OIL	A, H	
3579	ONONIS SPINOSA	A, E, H	
3580	ONOPORDUM ACANTHIUM	A, H	
3581	ONOSMODIUM VIRGINIANUM	A, H	
3582	OPHIOPOGON JAPONICUS	A, H	
3583	OPOPANAX CHIRONIUM	A, E, H	When used as an excipient, permitted for use only in combination with other permitted ingredients as part of a flavour or a fragrance proprietary excipient formulation. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3584	OPOPANAX OIL	E	Permitted for use only in combination with other permitted

			ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3585	OPUNTIA FICUS-INDICA	A, H	
3586	ORANGE	E	
3587	ORANGE FLOWER ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3588	ORANGE FLOWER OIL	A, E, H	When used internally, oxedrine is a mandatory component of orange flower oil. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
3589	ORANGE JUICE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3590	ORANGE JUICE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a

			fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3591	ORANGE OIL	A, E, H	When used internally, oxedrine is a mandatory component of orange oil. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
3592	ORANGE OIL BITTER	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavor, the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance, the total fragrance concentration in a medicine must be no more 1%. The warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' or words to that effect must be include on the medicine label unless the medicine is: a) for internal use; b) in preparations containing 1.4% or less of orange oil bitter; c) for use in soaps or bath or shower gels that are washed off the skin.
3593	ORANGE OIL BITTER COLDPRESSED	A, E, H	When used internally, oxedrine is a mandatory component of orange oil bitter coldpressed.

			The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams. The warning statement (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect) must be included on the medicine label unless the medicine is: a) for internal use; or b) in preparations containing 1.4% or less of orange oil bitter coldpressed; or c) for use in soaps or bath or shower gels that are washed off the skin.
3594	ORANGE OIL COLD PRESSED	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3595	ORANGE OIL DISTILLED	A, E, H	When used internally, oxedrine is a mandatory component of orange oil distilled. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
3596	ORANGE OIL SWEET	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Volume 4

			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3597	ORANGE OIL TERPENELESS	A, E, H	When used internally, oxedrine is a mandatory component of orange oil terpeneless. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
3598	ORANGE PEEL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3599	ORANGE PEEL DRIED BITTER	A, E, H	When used internally, oxedrine is a mandatory component of orange peel dried bitter. The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
3600	ORANGE PEEL OIL SWEET TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3601	ORANGE ROUGHY OIL	E	Only for use in topical medicines for dermal application.

3602	ORIGANUM MAJORANA	A, H	Beta-arbutin is a mandatory component of Origanum majorana. When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin. When for dermal application exclusively to the face: a) the concentration of beta-arbutin in the medicine must not be more than 7%; b) hydroquinone is a mandatory component; and c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%. When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%. When the plant preparation is oil or distillate, and the concentration of Origanum majorana oil or distillate within the medicine is more than 50%: a) the nominal capacity of the container must not be more than 50 mL; b) a restricted flow insert must be fitted on the container; and c) the following warning statement is required on the label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
3603	ORIGANUM OIL	E	Permitted for use only in combination with other ingredients as a fragrance.

Volume 4

			If used as a fragrance the total concentration in the medicine must be no more than 1%.
3604	ORIGANUM OIL SPANISH	A, E, H	
3605	ORIGANUM VULGARE	A, E, H	
3606	ORNITHINE	A, E	
3607	ORNITHINE ASPARTATE	A, E	
3608	ORNITHINE MONOHYDROCHLORIDE	A, E	
3609	ORNITHOGALUM UMBELLATUM	A, H	
3610	OROSTACHYS FIMBRIATA	A, H	
3611	OROXYLUM INDICUM	A, H	
3612	ORRIS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3613	ORRIS CONCRETE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3614	ORRIS ROOT EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3615	ORRIS ROOT OIL	A, E, H	
3616	ORRIS ROOT RESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour.

			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3617	ORTHO-TERT-BUTYLCYCLOHEXYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3618	ORTHOSIPHON ARISTATUS	A, H	
3619	ORYZA SATIVA	A, E, H	
3620	ORYZANOL	E	
3621	OSBECKIA CHINENSIS	A, H	
3622	OSMANTHUS ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3623	OSMANTHUS FRAGRANS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3624	OTTELIA ALISMOIDES	A, H	
3625	OXACYCLOHEPTADEC-11-EN-2-ONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.

Volume 4

			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3626	OXACYCLOHEXADECAN-2-ONE	E	Only for use in topical medicines for dermal application.
3627	OXACYCLOHEXADECEN-2-ONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3628	OXALIC ACID	H	Only for use as an active homoeopathic ingredient. The total concentration of oxalic acid in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.
3629	OXALIS ACETOSELLA	A, H	
3630	OXIDISED MAIZE STARCH	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3631	OXIDISED TAPIOCA STARCH	E	
3632	OXYBENZONE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 10%. When used in primary sunscreen products, the following warning statements are required on the

			label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3633	OYSTER	E	The following warning statement is required on the medicine label: - (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.
3634	OYSTER SHELL	A, E, H	The following warning statement is required on the medicine label: - (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.